4-[4-(1-methyl-1H-pyrazol-4-yl)-1-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]-1H-imidazol-5-yl]-benzonitrile Property

Boiling point:

632.8±55.0 °C(Predicted)

Density 

1.26±0.1 g/cm3(Predicted)

solubility 

DMSO:18.58(Max Conc. mg/mL);51.99(Max Conc. mM)
DMF:20.0(Max Conc. mg/mL);55.96(Max Conc. mM)
DMF:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.4(Max Conc. mM)
Ethanol:13.37(Max Conc. mg/mL);37.41(Max Conc. mM)

form 

A crystalline solid

pka

4.29±0.61(Predicted)

color 

Off-white to light yellow

Hazard and Precautionary Statements (GHS)

4-[4-(1-methyl-1H-pyrazol-4-yl)-1-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]-1H-imidazol-5-yl]-benzonitrile Chemical Properties,Usage,Production

Description

BAZ2A/B are bromodomain-containing proteins whose biological function, while not yet confirmed, is believed to function similarly to ACF1, the Drosophila BAZ2B ortholog. ACF complexes play roles in establishing regular nucleosome spacing during chromatin assembly and influencing different remodeling outcomes at target loci. A rare allele of BAZ2B has been identified to be a predictor of Sudden Cardiac Death. BAZ2-ICR is a small molecule inhibitor of BAZ2A (K_d = 109 nM; IC₅₀ = 130 nM) and BAZ2B (K_d = 170 nM; IC₅₀ = 180 nM) bromodomains. It demonstrates 15-fold selectivity for binding BAZ2A/B over CECR2 and >100-fold selectivity over all other bromodomains. BAZ2-ICR has been shown to displace BAZ2 bromodomains in living cells by demonstrating accelerated FRAP recovery at 1 μM in the BAZ2A FRAP assay. See the Structural Genomics Consortium (SGC) website for more information.

Uses

BAZ2-ICR is a selective BAZ2 bromodomain inhibitor (IC50 values are 130 and 180 nM for BAZ2A and BAZ2B respectively). Exhibits 15-fold selectivity for the BAZ2 bromodomain over the CERC2 bromodomain and >100-fold selectivity over a range of other bromodomains. Accelerates FRAP recovery in a BAZ2A FRAP assay.

storage

Store at -20°C